[Turn over

Total No. of printed pages = 4

MP	'H 1	03 '	o lette						BINAC	HOWDHURY CENTRAL L BRARY (GIMT & SIPS)	
Roll	No. o	of car	ndidate						H Day	Azara, Hatkhowapara Guwanau - 781017	
							000	10		All Historian and	
			35.73				202		LVE		
			M.Ph						lar) Exan	nination	
			n all	M					CEUTICS		
					(New	Reg	ulati	on)		
Full	Mar	ks – '	75							Time – Three hour	rs.
							101				
		Tł	ne figures	in th	e mar	gin i	ndica	te full	l marks for	the questions.	
1.	Ans	wer t	he follow	ing qu	uestio	ns:				$(20 \times 1 = 20)$))
	(i)	- 100	e ———dition		— D	issol	ution	Appa		used for maintaining Sir	k
		(a)	I					(b)	III		
		(c)	IV					(d)	V		
	(ii)		ich of the		llowin	g te	chniq	ue is	s most su	itable for studying dru	ıg
		(a)	Therma	l anal	lysis			(b)	XRD	o sixipalare variety	1
		(c)	Hot stag	ge mio	crosco	ру		(d)	Single Cr	rystal X Ray	
	(iii)	Wh	ich of the	follov	ving i	s call	ed Pr	e-mai	rketing Va	lidation?	
		(a)	Prospec	tive V	alida	tion		(b)	Retrospe	ctive Validation	
		(c)	Concurr	ent V	alida	tion		(d)	Revalida	tion	
	(iv)	In 7	Cablet Con	mpres	sion S	Stres	s is e	qual t	0:		
		(a)	Force/A	rea				(b)	Force/Str	ain	
		(c)	Area/Fo	rce				(d)	None of t	he above	
		-							2		

(v)		is a series of test	that	measure the performance capability
	of th	ne equipment		
	(a)	Installation Qualification	(b)	Design Qualification
	(c)	Performance Qualification	(d)	Operation Qualification
(vi)	The	following equation holds for Fe	orce I	Distribution during compaction
	(a)	$F_A = F_L + F_D$	(b)	$F_A = F_L F_D$
	(c)	$F_A = F_L / F_D$	(d)	None of above
(vii)	Solu	bility of acidic or basic drug m	ust b	e determine over the pH range of
	(a)	2-10	(b)	1-8
	(c)	3-12	(d)	1-5
(viii)	BET	Theory of adsorption is used t	o det	ermine
	(a)	Particle Volume	(b)	Particle Shape
	(c)	Surface Area	(d)	Particle size
(ix)	The	ICH Code Q1B stands for the	guide	line title
	(a)	Stability of new drug substan	ce an	d product
	(b)	Stability testing of new dosag	e forr	m
	(c)	Evaluation of stability data		
	(d)	None of the above		
(x)	Whi	ch of the following dosage	form	is regarded as thermodynamically
	stab	le?		
	(a)	Emulsion	(b)	Suspension
	(c)	Microemulsion	(d)	Multiple emulsion
(xi)	The level		ation	is more suitable for three or more
	(a)	Full Factorial Design	(b)	Fractional Factorial Design
	(c)	Star Design	(d)	Central Composite design
(xii)	Whi	ch is of the following isn't a me	chan	ism of Tablet Compression
	(a)	Fragmentation	(b)	Rearrangement
	(c)	Chipping	(d)	Deformation

2

MPH 103 T

	(xii	i) Wh	ich of the following technique i	s not	suitable fo	r drug-excipie	ent study?
		(a)	HPLC	(b)	DSC	SIKIN OF IOWALLI	
		(c)	DRS	(d)	NMR	(GIV	TAY CENTRAL LIBR VT.4 (185) Helinowapara
	(xiv) Acc	ording to BCS classification Cla	ass II	drugs are	Gindaly	ali - 781017
		(a)	High Solubility and High Per	meab	ility		
		(b)	Low Solubility and High Perr	neabi	lity		
		(c)	High Solubility and Low Perr	neabi	lity		
		(d)	Low Solubility and Low Perm	eabil	ity		
	(xv)	Solu	ability of acidic or basic drug m	ust b	e determin	e over the pH	range of
		(a)	2-10	(b)	1-8		
		(c)	3-12	(d)	1-5		
	(xvi) V	What is the meaning of "current	" acc	ording to G	MP regulatio	n?
	(xvi	i) A	NOVA stands for —	-			
	(xvi	ii) D	Define Heckel plot.				
	(xix) –	is a common n	netho	d for statis	tical optimiza	ation.
	(xx)	W	Vhat do you mean by IQ faciliti	es?			
	Ans	wer a	any seven from the following:				$(7 \times 5 = 35)$
	(a)	Writ	te the content of Master formul	a as j	per WHO.		
	(b)		at are dependent and independent are dependent are dependent and independent are dependent are dependent are dependent are dependent and independent are dependent are dependent are dependent and independent are dependent are d				
2	(c)	Give	e a brief description of physics of	of tab	let compre	ssion.	
	(d)	Diffe	erentiate between GMP, QC an	d QA			
	(e)	Disc	cuss the factors affecting dissolu	ation.			
	(f)	Writ	te a brief note on the theoretica	lasp	ects of SMI	EDDS.	
	(g)		cribe the applications of factorial formulations.	toria.	designs	and contour	designs in
	(h)	Diffe	erentiate IQ, DQ, OQ and PQ is	n Pha	rmaceutic	al Validation.	
	(i)	Writ	te a brief note on total quality r	nana	gement.		

3. Answer any two out of three:	3.	Answer	any two	out of three:	
---------------------------------	----	--------	---------	---------------	--

 $(2 \times 10 = 20)$

- (a) (i) Write a brief note of linearity concept of significance. (4)
 - (ii) Write in detail on various aspects of preformulation studies in dosage form designs and its importance. (6)
- (b) (i) Give the advantages of Pharmaceutical validation. Explain in details various Phases of Equipment Validation. (5)
 - (ii) Explain in details the different types of Process validation. Give the change Control Classifications. (5)
- (c) (i) Write in details on various guidelines for Plant Layout and Services as per GMP.
 - (ii) Mention the objectives of cGMP. (4)